21 assets in Metabolic Disease

Therapeutic assets addressing Metabolic Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Semaglutide Metabolic Disease	Nordsjaellands Hospital	P4	A (81)
Metformin Metabolic Disease	Jinnah Sindh Medical University	P4	BBB (77)
Tirzepatide Metabolic Disease	Washington University School of Medicine	P4	BBB (74)
Busulfanum Metabolic Disease	University of Rochester	P2	BB (66)
Glucose, Anhydrous Metabolic Disease	University Hospital Schleswig-Holstein	P4	BB (65)
Terazosin Metabolic Disease	I.R.C.C.S. Fondazione Santa Lucia	P4	BB (65)
Gnr-055 Metabolic Disease	AO GENERIUM	P2/3	BB (64)
Nexiguran Ziclumeran Metabolic Disease	Intellia Therapeutics	P3	B (60)
4H-1-BENZOPYRAN-4-ONE, 8-.BETA.-D-GLUCOPYRANOSYL-7-HYDROXY-3-(4-HYDROXYPHENYL)- Metabolic Disease	Ruijin Hospital	P2	CCC (53)
Cyclophosphamide Metabolic Disease	University of Rochester	P2	CCC (53)
Fludarabine Metabolic Disease	University of Rochester	P2	CCC (53)
pf-08653944 Metabolic Disease	Pfizer	P2	CCC (53)
pf-08653945 Metabolic Disease	Pfizer	P2	CCC (53)
Vericiguat Metabolic Disease	University of Alabama at Birmingham	P2	CCC (53)
Testosterone Undecylate Metabolic Disease	Royal College of Surgeons, Ireland	P1/2	CCC (52)
Verenafusp Alfa Metabolic Disease	AO GENERIUM	P1	CC (47)
Bicalutamide Metabolic Disease	Royal College of Surgeons, Ireland	N/A	D (30)
Extra Virgin Olive Oil Metabolic Disease	University of Peloponnese	N/A	NR ()